Evidence map›Paper›PMID 26870808›Full record

ArticleEBioMedicine2015

Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.

Linda S Robinson, Ashley Hendrix, Xian-Jin Xie, Jingsheng Yan, Sara Pirzadeh-Miller, Mary Pritzlaff, Parker Read, Sarah Pass, David Euhus, Theodora S Ross

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Linda S RobinsonDepartment of Cancer Genetics, University of Texas Southwestern Medical Center's Harold Simmons Comprehensive Cancer Center, Dallas and Moncrief Cancer Institute, Fort Worth, TX, USA.
Ashley HendrixDepartment of Cancer Genetics, University of Texas Southwestern Medical Center's Harold Simmons Comprehensive Cancer Center, Dallas and Moncrief Cancer Institute, Fort Worth, TX, USA.
Xian-Jin XieDepartment of Biostatistics and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, USA; Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center,Dallas, TX, USA.
Jingsheng YanDepartment of Biostatistics and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, USA; Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center,Dallas, TX, USA.
Sara Pirzadeh-MillerDepartment of Cancer Genetics, University of Texas Southwestern Medical Center's Harold Simmons Comprehensive Cancer Center, Dallas and Moncrief Cancer Institute, Fort Worth, TX, USA.
Mary PritzlaffDepartment of Cancer Genetics, University of Texas Southwestern Medical Center's Harold Simmons Comprehensive Cancer Center, Dallas and Moncrief Cancer Institute, Fort Worth, TX, USA.
Parker ReadDepartment of Cancer Genetics, University of Texas Southwestern Medical Center's Harold Simmons Comprehensive Cancer Center, Dallas and Moncrief Cancer Institute, Fort Worth, TX, USA.
Sarah PassDepartment of Cancer Genetics, University of Texas Southwestern Medical Center's Harold Simmons Comprehensive Cancer Center, Dallas and Moncrief Cancer Institute, Fort Worth, TX, USA.
David EuhusDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Theodora S RossDepartment of Cancer Genetics, University of Texas Southwestern Medical Center's Harold Simmons Comprehensive Cancer Center, Dallas and Moncrief Cancer Institute, Fort Worth, TX, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
The University of Texas Southwestern Medical Center · USCancer Genetics (United States) · USJohns Hopkins Hospital · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
NCI NIH HHS 5P30CA142543NCI NIH HHS P30 CA142543
6 · The paper itself

Abstract

backgroundThe US Preventative Service Task Force recommends that physicians perform a genetic risk assessment to identify women at risk for BRCA1/2 mutations associated with hereditary breast and ovarian cancer (HBOC) syndrome. However, outcomes data after a diagnosis of HBOC syndrome especially in diverse populations, are minimal. Here we asked if genetic screening of high-risk underserved women identified in the mammogram population reduces cancer incidence.

methodsWe evaluated 61,924 underserved women at screening mammography for family histories suggestive of HBOC syndrome over the course of 21 months. Data were collected retrospectively from patients at two safety net hospitals through chart review. A computer model was used to calculate the long-term effect of this screening on cancer incidence by assessing both the mutation detection rate and the completion of prophylactic surgeries in BRCA1/2 mutation carriers.

findingsWe identified 20 of the 85 (23.5%) expected BRCA1/2 mutation carriers in the underserved population. The frequencies of prophylactic mastectomies and oophorectomies in the mutation carriers were 25% and 40%, respectively. Using these data, our model predicted only an 8.8% reduction in both breast and ovarian cancer in the underserved patients. This contrasts with a 57% reduction in breast cancer and 51% reduction in ovarian cancer in an insured reference population. Our data indicate that underserved patients with HBOC syndrome are difficult to identify and when identified are limited in their ability to adhere to NCCN guidelines for cancer prevention.

interpretationScreening for women at risk for HBOC syndrome in mammogram populations will only prevent cancers if we can increase compliance with management guidelines. This study provides prototypic baseline data for step-wise analysis of the efficacy of the use of family history analysis in the mammography setting for detection and management of HBOC syndrome.

Indexed as

Computer SimulationFemaleGenes, BRCA1Genes, BRCA2Genetic TestingHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHumansMammographyMass ScreeningModels, BiologicalMutationMutation RatePopulation SurveillanceTexasBRCA1/2Genetic testingHereditary breast and ovarian cancer syndromePopulation screeningUnderserved

Identifiers

PMID26870808
PMCPMC4740331
OpenAlexW1841641218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.